Perspective Therapeutics Share Price Today

Perspective Therapeutics Q3 Results: Loss narrows, analysts cut targets

Perspective Therapeutics posted a Q3 loss of 27 cents per share, narrowing from 35 cents in the prior year. Quarterly sales fell to $20.000K from $209.000K in the year-ago period. Wedbush cut its price target to $7 from $9, maintaining an Outperform rating. Piper Sandler lowered its target to $8 from $14, keeping an Overweight rating. Shares traded down 2.4% to $0.84 following the earnings announcement.

Perspective Therapeutics Q3FY26 Results: Net loss $32.4m, cash $202m

Net loss widened to $32.4 million in Q3FY26 from $26.0 million in Q3FY25. Cash and short-term investments stand at $202 million, sufficient into 2028. R&D expenses rose 28.6% YoY to $26.1 million driven by clinical trials. FDA End-of-Phase 2 meeting targeted for Q1 2027 for NET program. PSV359 received Fast Track Designation for FAP-positive solitary fibrous tumors.

Perspective Therapeutics to present VMT01 melanoma data at SITC 2026

Data from [212Pb]VMT01 program accepted for presentation at SITC 41st Annual Meeting. Event scheduled for November 4 to 8, 2026, in Phoenix, Arizona. Presentation features phase I/IIa trial results for previously treated metastatic melanoma. Interim analysis showed two responders out of seven patients in monotherapy cohort.

Perspective Therapeutics signs clinical deal with Merck for cancer combo

Perspective Therapeutics partners with Merck to combine PSV359 with Keytruda. Collaboration amends ongoing Phase 1/2a study for FAP-α positive solid tumors. Merck provides pembrolizumab at no cost while Perspective sponsors the study. Trial targets non-small cell lung cancer and colorectal cancer patients.

Perspective Therapeutics to present [212Pb]VMT-α-NET data at EORTC-NCI-AACR 2026

Perspective Therapeutics announced acceptance of [212Pb]VMT-α-NET data for the 38th EORTC-NCI-AACR Symposium 2026. Data covers cohort-level safety and efficacy for Cohorts 1–3 in advanced SSTR2+ neuroendocrine tumors. Presentation by Vikas Prasad is scheduled as a poster session on November 20, 2026, in Barcelona. Previous interim data with an April 17, 2026 cut-off were presented at ASCO 2026 in May 2026. The study targets patients with unresectable or metastatic SSTR2-positive tumors without prior radiopharmaceutical therapy.

Perspective Therapeutics Q2 EPS beats estimates as sales miss consensus

Perspective Therapeutics reported Q2 EPS of $(0.22), beating estimates by 15.38%, while sales of $81.000K missed expectations. The net loss widened to $26.8 million amid rising R&D costs, but strong liquidity supports clinical trials through late 2027.